News and Media

AdvanceCOR GmbH announces favourable results of a clinical phase II study on Revacept vs. placebo in patients with symptomatic stenosis of the carotid artery suffering from ischemic stroke

AdvanceCOR GmbH announces successful completion of preclinical development of thyroid stimulating hormone receptor (TSHR) peptide 19 for the treatment of patients with Graves´ disease and orbitopathy

Completion of patient recruitment in a clinical phase II study on Revacept

advanceCOR GmbH secures financing for proof of concept patient studies

AdvanceCOR GmbH Has Received Funding from the German Federal Ministry of Education (BMBF) and the Bavarian Research Foundation

AdvanceCOR GmbH closes a second financing round with MIG AG as lead investor

Press release Download

(August 2015)

Press release Revacept Phase II

Press release financing round